Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
25. März, 2018, 10:29
Checkpoint inhibitors are a first-line therapy for advanced melanoma, though their use is limited by diarrhea and colitis. The aim of our study was to determine the risk of these toxicities associated with immunotherapy in advanced melanoma. Electronic databases were searched through June 2017 for prospective studies reporting the risk of diarrhea and colitis in advanced melanoma treated with anti–programmed death-1 (PD-1) or anti–cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitors. Standardized definitions assessed the grade of diarrhea and colitis. Pooled incidence and weighted relative risk estimates with 95% confidence intervals (CI) were estimated using random effects model. Eighteen studies were included: 6 studies (1537 patients) with P…